|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Loss before tax for the year | ||||
| Share based compensation | ||||
| Issuance of restricted shares to investors | ||||
| Depreciation and amortization | ||||
| Decrease in other current receivables | ||||
| Impairment of intangible assets | ||||
| Impairment of goodwill | ||||
| Increase (decrease) in trade payables | ||||
| Increase (decrease) in other payables | ||||
| Increase in other liabilities | ||||
| Revaluation of financial liabilities at fair value | ||||
| Interest expenses and revaluation of convertible notes | ||||
| Revaluation of convertible notes | ||||
| Financial expenses due to bridge loans principal amounts | ||||
| Remeasurement of investment in associated company | ||||
| Interest expenses due to short term loan | ||||
| Share in losses of associated companies, net | ||||
| Issuance of ordinary shares and warrants due to underwriter fees | ||||
| Issuance cost due to inducement Alpha warrant B’s exercise price | ||||
| Issuance of ordinary shares due to commitment fee | ||||
| Issuance of ordinary shares due to commitment/facility fee | ||||
| SPAC transaction - listing costs | ||||
| Net cash flow used in operating activities | ||||
| Cash flows from investing activities: | ||||
| Purchase of property, plant and equipment | ||||
| Capitalized development cost | ||||
| Net cash flow used in investing activities | ||||
| Cash flows from financing activities: | ||||
| Repayment of short-term loan | ||||
| Repayment of convertible notes | ||||
| Payment of lease liabilities | ||||
| Repayment of bridge loans | ||||
| Repayment of pre-paid advances/ advance payment for equity, net | ||||
| Proceeds from issuance of ordinary shares and pre-funded warrants | ||||
| Exercise of warrants B (see note 14 B.3) | ||||
| Exercise of warrants and pre-funded warrants into ordinary shares | ||||
| Proceeds from issuance of convertible notes and warrants, net | ||||
| Advance payment for equity, net (see note 10) | ||||
| Repayment of bridge loans (see note 9) | ||||
| Proceeds from short term loan | ||||
| Proceeds from issuance of bridge loans and warrants | ||||
| Proceeds from issuance of promissory note (see note 8.C) | ||||
| Issuance of shares in the SPAC transaction, net | ||||
| Net cash flow provided by financing activities | ||||
| Increase (decrease) in cash and cash equivalents | ||||
| Cash and cash equivalents at beginning of year | ||||
| Exchange rate differences on cash and cash equivalent | ||||
| Cash and cash equivalents at end of year | ||||
| Appendix A – Non-cash transactions during the year: | ||||
| Conversion of financial liability into ordinary shares | ||||
| Conversion of warrants A to ordinary shares (see note 14.B.3) | ||||
| Conversion of bridge loans and derivative financial liability to ordinary shares | ||||
| Exercise of options and warrants into ordinary shares | ||||
| Conversion of convertible notes to ordinary shares | ||||
| Conversion of liability to ordinary shares (see note 14) | ||||
| Conversion of bridge loans into ordinary shares and warrants | ||||
| Conversion of convertible notes and warrants into ordinary shares | ||||
| Exercise of cashless options into ordinary shares | ||||
| Exercise of warrants and pre-funded warrants into ordinary shares | ||||
| Issuance cost | ||||
| Other current receivable in connection to exercise of Series A Common Warrant | ||||
| Remeasurement of investment in associated company | ||||
| Issuance of warrants to the placement agent in connection to RBW May agreement | ||||
Loading...
